Eye ointments glaucoma implants risks are now under renewed scrutiny after new research linked commonly used petrolatum-based eye ointments to swelling and rupture of a widely used glaucoma device. Scientists from Nagoya University in Japan report that these ointments can severely compromise the PRESERFLO MicroShunt, an implant used in glaucoma treatment across more than 60 countries.
The findings, published in Graefe’s Archive for Clinical and Experimental Ophthalmology, combine real-world clinical cases with laboratory testing, making this the first study to clearly demonstrate how eye ointments glaucoma implants interact at a material level.
Eye ointments glaucoma implants and device safety
Glaucoma is a chronic eye disease that damages the optic nerve and can lead to irreversible vision loss. It is often caused by elevated pressure inside the eye due to impaired fluid drainage. To manage this pressure, surgeons increasingly rely on the PRESERFLO MicroShunt, a tiny filtration device designed to improve fluid outflow with fewer complications than traditional surgery.
The MicroShunt is made from a flexible polymer known as SIBS, chosen for its biocompatibility and resistance to inflammation. However, researchers found that this material has a high affinity for oil-based substances, making it vulnerable when exposed to petrolatum-based eye ointments.
How eye ointments glaucoma implants swell
In the clinical portion of the study, researchers examined seven glaucoma patients whose MicroShunt implants were later removed. In three cases where the implant was exposed and patients were treated with petrolatum-based eye ointments, all devices showed significant swelling, and two had ruptured.
By contrast, implants that remained covered by eye tissue and were not exposed to ointments showed no structural changes. In a critical comparison case, one exposed implant that did not come into contact with ointment also showed no swelling, pointing directly to ointment exposure as the cause.
Eye ointments glaucoma implants confirmed in the lab
Laboratory experiments reinforced these observations. Unused MicroShunts immersed in petrolatum-based ointment swelled rapidly. Within 24 hours, the implant diameter increased by nearly 45%, while chemical analysis revealed that oil compounds made up almost half the device’s weight. After three months, oil content rose to more than 70%.
These changes explain why swollen implants become fragile and prone to fracture during surgery or removal.
Clinical implications for eye ointments glaucoma implants
The study highlights a major gap between manufacturer guidance and everyday clinical practice. While device instructions warn against contact with petrolatum-based products, this precaution is not consistently followed.
Researchers urge clinicians to avoid petrolatum-based eye ointments in patients with MicroShunt implants, especially when the device is exposed. They also stress the need for greater awareness of how chemical interactions can affect medical implants.
As glaucoma care continues to rely on advanced implant technologies, the study underscores a clear message: understanding how eye ointments glaucoma implants interact is essential to preventing avoidable complications and protecting patients’ vision.
